Stay updated with breaking news from Daniel Hicklin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are...
By Dean Seal Shares of Werewolf Therapeutics shot higher after the company presented Phase 1 trial data establishing proof of mechanism for its lead clinical...
Key Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are...
MedCity News Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines. Shares0 Two more biotech companies are joining the public markets. Werewolf Therapeutics and Vaccitech priced their respective IPOs late Thursday, raising a combined $230 million for multiple clinical trials. Werewolf was able to boost the size of its deal, ...